glp 1 triple agonist PDB-101: Molecule of the Month: GLP-1 Receptor Agonists A review of an investigational

Much of what we know comes from animal studies

[DOI] [PubMed] [Google Scholar] 33.Higgins JPT, Thomas J, Chandler J, et al (editors)

The brand publishes contact information, pricing references, and disclosures explaining that compounded GLP-1 medications are not FDA-approved finished drug products

Future research should develop longitudinal datasets to enable analysis of weight loss and side effects in the context of dosage escalations, while exploring genetic factors, which could then inform how genetics might be leveraged in clinical decision-making at treatment initiation and beyond

saying they currently take the medications